Screening Lab
Photo of Mike Klemba
Welcome to VTCDDSL!
The Virginia Tech Center for Drug Discovery Screening Laboratory (VTCDDSL) assists researchers to develop and carry out high-throughput assays. The laboratory is BSL2 certified and can do both cell-based and enzyme-based screening assays. The facility is available to the Virginia Tech community and users have access to over 40,000 chemical compounds.
Purchase of the equipment for the VTCDDSL was made possible by funds from the Fralin Life Sciences Institute.
Facility instruments are compatible with 96-well and 384-well microplates. Other microplate types may be used on select instruments.
We have a number of compound libraries available to researchers including a library of FDA-approved drugs, a natural-products library, a unique transition-metal complex library developed by Dr. Joe Merola, a brominated fragment library, a kinase-targeted library, as well as other libraries designed to maximize structural and chemical diversity. (See table below). Please note that commercial compound collections change over time as compounds are added or removed. For specific information about our libraries, please contact the screening lab.
| Library | Description | # cmpds |
|---|---|---|
Wide range of biological activities and structural diversity |
2,320 |
|
| Analyticon Discovery Academic NATx Library |
“Compounds based on bioactive natural products (70 scaffolds) further modified with both natural and unusual pharmacophore groups | 5,000 |
Custom selection from the Chembridge DiverSet |
30,000 |
|
Natural products with known bioactivity and good availability |
1,500 |
|
For fragment-based drug design (bromine incorporation facilitates identification of binding sites by x-ray crystallography) |
490 |
Library |
Description |
# cmpds |
ApexBio DiscoveryProbeTM Clinical and FDA-Approved Library |
Approved drugs and compounds in clinical trials |
2,726 |
Potent, selective and cell-permeable compounds that inhibit or activate target molecules involved in the infection process |
367 |
|
Structurally diverse, medicinally active, and cell permeable |
467 |
|
Structurally diverse inhibitors for kinases including RTKs, PI3K, Aurora Kinase, CDK, and MEK (most inhibitors competitive with ATP) |
273 |
|
Inhibitors and regulators targeting diverse protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc) , lipid kinases (PI3K, PI4K, SK, etc), and carbohydrate kinases. |
2,168 |
|
Compound targets relevant to lipid metabolism include ATGL, MAGL, FAAH, acetyl-CoA carboxylase, FASN, and others. |
304 |
|
Merola Tailored Transition-Metal Library (TTMC) |
Numerous compounds have demonstrated anti-mycobacterial activity and activity against S. aureus including strains of MRSA. Custom variants easily synthesized. |
110 |